RARE
RARE clinical trials: Ultragenyx Pharmaceutical Inc.
Every trial on ClinicalTrials.gov where Ultragenyx Pharmaceutical Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 91
- Trials linked
- 63
- As lead sponsor
- 28
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
RARE on the catalyst calendar · RARE registry changes
- Primary completion Jul 10, 2026ActualPhase 3NCT06617429Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc · Angelman SyndromeTerminatedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2032Sponsor estimateNo phase registeredNCT04783428Tumor-induced Osteomalacia Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · Tumor-induced Osteomalacia (TIO)Active, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026ActualPhase 2NCT07157254A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc · Angelman SyndromeTerminatedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026ActualPhase 3NCT06415344Long-term Extension of GTX-102 in Angelman SyndromeUltragenyx Pharmaceutical Inc · Angelman SyndromeTerminatedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2025ActualPhase 3NCT05768854Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2025ActualPhase 2/Phase 3NCT05125809Setrusumab vs Placebo for Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaActive, not recruitingRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2036Sponsor estimateNo phase registeredNCT06636383Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · Glycogen Storage Disease Type IaRecruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT07511556First-in-human Study of UX016 in GNEMUltragenyx Pharmaceutical Inc · GNE MyopathyRecruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2038Sponsor estimateNo phase registeredNCT07855562MPS IIIA Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · MPS IIIANot yet recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 3NCT06636071Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1/Phase 2NCT04884815A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson DiseaseUltragenyx Pharmaceutical Inc · Wilson DiseaseActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2024ActualPhase 3NCT05139316A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease...Ultragenyx Pharmaceutical Inc · Glycogen Storage Disease Type IACompletedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 2/Phase 3NCT02716246Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHUltragenyx Pharmaceutical Inc · MPS IIIARecruitingRARELeadABEOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT05933200A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODUltragenyx Pharmaceutical Inc · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Active, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT05345171Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Pharmaceutical Inc · OTC DeficiencyActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2032Sponsor estimateNo phase registeredNCT03651505X-linked Hypophosphatemia Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · X-linked HypophosphatemiaActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2032Sponsor estimateNo phase registeredNCT03604835Mucopolysaccharidosis VII Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · Mucopolysaccharidosis VIIRecruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03775174Expanded Access to MepseviiUltragenyx Pharmaceutical Inc · MPS VIIAvailableRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03773770Expanded Access to TriheptanoinUltragenyx Pharmaceutical Inc · Long Chain Fatty Acid Oxidation DisordersAvailableRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT04360265Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIAUltragenyx Pharmaceutical Inc · Mucopolysaccharidosis IIIAEnrolling by invitationRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2035Sponsor estimateNo phase registeredNCT04632953Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring ProgramUltragenyx Pharmaceutical Inc · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Active, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimateNo phase registeredNCT03636438Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC DeficiencyUltragenyx Pharmaceutical Inc · Ornithine Transcarbamylase (OTC) DeficiencyActive, not recruitingRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2025ActualNo phase registeredNCT03970278Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type IaUltragenyx Pharmaceutical Inc · Glycogen Storage Disease Type IACompletedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2025ActualPhase 1/Phase 2NCT04259281A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeUltragenyx Pharmaceutical Inc · Angelman SyndromeCompletedRARELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2022ActualPhase 2NCT05312697Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc · Osteogenesis ImperfectaTerminatedRARELeadMREOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 66 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner